Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Assets (2020 - 2025)

Historic Assets for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $785.1 million.

  • Mirum Pharmaceuticals' Assets rose 1755.1% to $785.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $785.1 million, marking a year-over-year increase of 1755.1%. This contributed to the annual value of $670.8 million for FY2024, which is 373.22% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Assets stood at $785.1 million, which was up 1755.1% from $725.8 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Assets peaked at $785.1 million during Q3 2025, and registered a low of $222.2 million during Q1 2021.
  • Moreover, its 5-year median value for Assets was $443.6 million (2023), whereas its average is $485.2 million.
  • The largest annual percentage gain for Mirum Pharmaceuticals' Assets in the last 5 years was 9547.33% (2024), contrasted with its biggest fall of 265.14% (2024).
  • Over the past 5 years, Mirum Pharmaceuticals' Assets (Quarter) stood at $294.7 million in 2021, then rose by 19.77% to $352.9 million in 2022, then soared by 83.23% to $646.6 million in 2023, then increased by 3.73% to $670.8 million in 2024, then increased by 17.05% to $785.1 million in 2025.
  • Its Assets stands at $785.1 million for Q3 2025, versus $725.8 million for Q2 2025 and $690.2 million for Q1 2025.